ProMIS Neurosciences マネジメント

マネジメント基準チェック /44

現在、CEO に関する十分な情報がありません。

主要情報

Neil K. Warma

最高経営責任者

US$40.0k

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	3.5yrs
取締役会の平均在任期間	6.7yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Neil K. Warma (61 yo)

less than a year

在職期間

US$40,000

報酬

Mr. Neil K. Warma, MBA, serves as Chief Executive Officer and President of ProMIS Neurosciences, Inc. from August 1, 2024 and has been its Director since December 30, 2023 and was its Interim Chief Executi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Eugene Williams	Co-Founder & Chairman	9.4yrs	US$275.00k	0.79% $ 147.1k
Neil K. Warma	CEO, President & Director	less than a year	US$40.00k	データなし
Neil Cashman	Co-Founder	20.5yrs	US$378.82k	0.57% $ 105.7k
Gavin Malenfant	Chief Operating Officer	3.1yrs	US$435.90k	0.013% $ 2.4k
Daniel Geffken	Chief Financial Officer	7.7yrs	US$142.40k	0.029% $ 5.4k
Johanne Kaplan	Chief Development Officer	8.3yrs	US$525.57k	0.024% $ 4.4k
David Wishart	Chief Physics Officer	3.5yrs	データなし	データなし
Dennis Chen	Head of Manufacturing & Senior Consultant	no data	データなし	データなし
Larry Altstiel	Chief Medical Officer	2.6yrs	データなし	データなし

3.5yrs

平均在職期間

65yo

平均年齢

経験豊富な経営陣: PMNの経営陣は経験豊富であると考えられます ( 3.5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Eugene Williams	Co-Founder & Chairman	9.4yrs	US$275.00k	0.79% $ 147.1k
Neil K. Warma	CEO, President & Director	3.5yrs	US$40.00k	データなし
Neil Cashman	Co-Founder	17.8yrs	US$378.82k	0.57% $ 105.7k
William Wyman	Independent Director	10.7yrs	US$40.00k	0.31% $ 57.9k
William Mobley	Member of Scientific Advisory Board	7.4yrs	データなし	データなし
Patrick Kirwin	Independent Director	9.4yrs	US$40.00k	0.49% $ 91.2k
Joshua Mandel-Brehm	Independent Director	3.2yrs	US$40.00k	0% $ 0
Sharon Cohen	Member of Scientific Advisory Board	6.7yrs	データなし	データなし
Andre Strydom	Member of Scientific Advisory Board	5.3yrs	データなし	データなし
Michelle Hastings	Member of Scientific Advisory Board	no data	データなし	データなし
Madge Shafmaster	Lead Independent Director	3.2yrs	US$40.00k	1.04% $ 191.7k
Carsten Korth	Member of Scientific Advisory Board	2.8yrs	データなし	データなし

6.7yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: PMNの取締役会は経験豊富であると考えられます ( 6.7年の平均在任期間)。

ProMIS Neurosciences マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44